Drug target optimization in chronic myeloid leukemia using innovative computational platform

Scientific Reports

Volumn 5, Issue , 2015, Pages 8190-

  Chuang, Ryan ^a   Hall, Benjamin A ^b,c   Benque, David ^b   Cook, Byron ^b,d   Ishtiaq, Samin ^b   Piterman, Nir ^e   Taylor, Alex ^b   Vardi, Moshe ^f   Koschmieder, Steffen ^g   Gottgens, Berthold ^h,i   Fisher, Jasmin ^b,j  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MICROSOFT RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f Rice University   (United States)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 6; PROTEIN BCL X; RAS PROTEIN;

ALGORITHM; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MODEL; BIOLOGY; CHRONIC MYELOID LEUKEMIA; COMPUTER SIMULATION; DRUG EFFECTS; GENE INACTIVATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES;

ALGORITHMS; APOPTOSIS; BCL-X PROTEIN; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; FUSION PROTEINS, BCR-ABL; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; IMATINIB MESYLATE; INTERLEUKIN-3; INTERLEUKIN-6; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; RAS PROTEINS;

EID: 84923093405     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08190     Document Type: Article

References (39)

1. Gallagher, R. & Appenzeller, T. Beyond reductionism. Science 284, 79-79, doi:DOI 10.1126/science.284.5411.79 (1999).
2. Chuang, H.-Y., Hofree, M. & Ideker, T. A decade of systems biology. Annu Rev Cell Dev Biol 26, 721-744 (2010).
3. Fisher, J. & Henzinger, T. A. Executable cell biology. Nat Biotechnol 25, 1239-1249 (2007).
4. Clarke, E. M., G. O. & Peled, D. Model Checking. (MIT Press, 1999).
5. Kauffman, S. A. Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol 22, 437-467 (1969).
6. Huang, S. Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery. J Mol Med (Berl) 77, 469-480 (1999).
7. Sanchez, L. & Thieffry, D. A logical analysis of the Drosophila gap-gene system. J Theor Biol 211, 115-141 (2001).
8. Schaub, M. A., Henzinger, T. A. & Fisher, J. Qualitative networks: a symbolic approach to analyze biological signaling networks. BMC Syst Biol 1, 4-4 (2007).
9. Lenaerts, T., Pacheco, J. M., Traulsen, A. & Dingli, D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematol-Hematol J 95, 900-907, doi:DOI 10.3324/haematol.2009.015271 (2010).
10. Schuringa, J. J., Chung, K. Y., Morrone, G. & Moore, M. A. S. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 200, 623-635 (2004).
11. Nanda, S., Moore, H. & Lenhart, S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210, 143-156, doi:DOI 10.1016/j.mbs.2007.05.003 (2007).
12. Deininger, M. W., Goldman, J.M. & Melo, J. V. Themolecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
13. Cook, B., F. J., Krepska, E. & Piterman, N. in 2th International Conference on Verification, Model Checking, and Abstract Interpretation Conference VMCAI'11. (ed Jhala, R. & Schmidt, D.) 134-149 (Springer Verlag).
14. Liu, F. et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 950-962, doi:10.1096/fj.01-0870com (2002).
15. Sonoyama, J. et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277, 8076-8082 (2002).
16. Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002).
17. Notari, M. et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107, 2507-2516 (2006).
18. Holyoake, T. L. et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97, 720-728 (2001).
19. Oetzel, C. et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 6, 1958-1968 (2000).
20. Hariharan, I. K., Adams, J. M. & Cory, S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 3, 387-399 (1988).
21. Uchida, M. et al. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. Stem Cells 22, 609-616 (2004).
22. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proceedings of the National Academy of Sciences of the United States of America 100, 7977-7982, doi:10.1073/pnas.1337088100 (2003).
23. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nature reviews. Drug discovery 8, 111-128, doi:10.1038/nrd2683 (2009).
24. Stanton, T. & Reid, J. L. Fixed dose combination therapy in the treatment of hypertension. Journal of human hypertension 16, 75-78, doi:10.1038/sj.jhh.1001312 (2002).
25. Zhang, S. et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature medicine 17, 461-469, doi:10.1038/nm.2309 (2011).
26. Bokhari, S. U., Gopal, U. M. & Duckworth, W. C. Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. The American journal of the medical sciences 325, 66-69 (2003).
27. Wu, Z., Zhao, X. M. & Chen, L. A systems biology approach to identify effective cocktail drugs. BMC Syst Biol 4 Suppl 2, S7, doi:10.1186/1752-0509-4-s2-s7 (2010).
28. Zhao, X. M. et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS computational biology 7, e1002323, doi:10.1371/journal.pcbi.1002323 (2011).
29. Seo, J. H. et al. A Specific Need for CRKL in p210(BCR-ABL)-Induced Transformation of Mouse Hematopoietic Progenitors. Cancer Res 70, 7325-7335, doi:Doi 10.1158/0008-5472.Can-10-0607 (2010).
30. Otsuka, T., Thacker, J. D., Eaves, C. J. & Hogge, D. E. Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest 88, 417-422, doi:10.1172/JCI115320 (1991).
31. Meng, Y. et al. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma 48, 2204-2212 (2007).
32. Goff, D. J. et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316-328 (2013).
33. Hehlmann, R. How I treat CML blast crisis. Blood 120, 737-747, doi:10.1182/blood-2012-03-380147 (2012).
34. Hasan, S., Bonde, B. K., Buchan, N. S. & Hall, M. D. Network analysis has diverse roles in drug discovery. Drug Discov Today 17, 869-874, doi: DOI 10.1016/j.drudis.2012.05.006 (2012).
35. Saadatpour, A. et al.Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS computational biology 7, e1002267, doi:10.1371/journal.pcbi.1002267 (2011).
36. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188, doi:10.1038/nature08543 (2009).
37. Delmore, J. E. et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell 146, 903-916, doi: DOI 10.1016/j.cell.2011.08.017 (2011).
38. Benque, D. et al. in Computer Aided Verification. Vol. 7358 Lecture Notes in Computer Science (eds P. Madhusudan & SanjitA Seshia) Ch. 50, 686-692 (Springer Berlin Heidelberg, 2012).
39. Taylor, A. et al. in ACM SIGCHI Conference on Human Factors in Computing Systems 493-502 (ACM, Paris, France, 2013).